Navigation Links
Nastech Announces Third Quarter 2007 Financial Results
Date:10/29/2007

w.nastech.com.

Nastech Forward-Looking Statements

Statements made in this press release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of Nastech to obtain additional funding; (ii) the ability of Nastech to attract and/or maintain manufacturing, research, development and commercialization partners; (iii) Nastech's and/or a partner's ability to successfully complete product research and development, including preclinical and clinical studies and commercialization; (iv) Nastech's and/or a partner's ability to obtain required governmental approvals; and (v) Nastech's and/or a partner's ability to develop and commercialize products that can compete favorably with those of competitors. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Nastech's most recent periodic reports on Form 10-K and Form 10-Q that are filed with the Securities and Exchange Commission. Nastech assumes no obligation to update and supplement forward-looking statements because of subsequent events.

Contacts:

Nastech

Ed Bell

Director, Investor Relations

(425) 908-3639

ir@nastech.com

Russo Partners, LLC

David Schull (Media)

(212) 845-4271

NASTECH PHARMACEUTICAL COMPANY INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In Thousands, Except Per Share Data)

Three Months Ended Nine Months Ended


'/>"/>

SOURCE Nastech Pharmaceutical Company Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... BASKING RIDGE, N.J. (PRWEB) December 17, 2014 ... Ipsen (Euronext: IPN; ADR: IPSEY), ... 120 mg (referred to as Somatuline®) was approved ... for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) ... differentiated, locally advanced or metastatic disease to improve ...
(Date:12/17/2014)... 2014 Audacity, a leading California-based health ... of the Huntsworth Health Group, is proud to announce ... In her role, Gonzales will serve as Senior Vice ... honored to welcome a talent of Jamie’s caliber to ... Fraikin. “She is a proven healthcare innovation leader and ...
(Date:12/17/2014)...   Synageva BioPharma Corp. (NASDAQ: ... rare disorders, announced today its presentation at the upcoming ... San Francisco, CA. Sanj ... present on Monday, January 12, 2015, at 9:00 a.m. ... live and may be accessed from the "Webcasts & ...
(Date:12/15/2014)... Limited (NASDAQ GS: SEED) (" Origin ", or the " ... China , today announced that the Company will ... 2014, before the market opens on Thursday, January 8, 2015. ... 8, 2015, at 8:00 a.m. ET / 9:00 p.m. ... participate in the call, please dial +1-888-346-8982 in ...
Breaking Biology Technology:Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 2Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 3
... 22 /PRNewswire/ - Do winery tasting rooms really help ... Vineland Research and Innovation Centre almost half of winery ... months of their visit. , "This research proves that ... the brand resulting in future sales," said Dr. Isabelle ...
... /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (TSX: AEZ; Nasdaq: ... focused on endocrine therapy and oncology, today presented ... orally-active tubulin and topoisomerase II inhibitor compound, AEZS-112, ... which may potentially provide a new therapeutic approach ...
... 500 Corporations, Universities, and Young Companies will Present at ... Mass., April 22 NSTI and CTSI today announced ... & development, funding, and commercialization partners will be showcased ... 4-6, 2009 at the George R. Brown Convention Center ...
Cached Biology Technology:Setting the Benchmark for Winery Tasting Room Research: An Emerging Region Gets a Global Perspective 2AEterna Zentaris Presents Phase 1 Results for AEZS-112 in Patients with Advanced Cancer and Lymphoma at AACR Annual Meeting in Denver 2AEterna Zentaris Presents Phase 1 Results for AEZS-112 in Patients with Advanced Cancer and Lymphoma at AACR Annual Meeting in Denver 3TechConnect Summit Brings the Global Technology Community to Houston, May 4-6, 2009 2TechConnect Summit Brings the Global Technology Community to Houston, May 4-6, 2009 3TechConnect Summit Brings the Global Technology Community to Houston, May 4-6, 2009 4
(Date:12/3/2014)... , Dec. 2, 2014 As part of ... Inception Technologies is pleased to announce the release of ... customers to collect the workforce data that they need. ... have been left by existing readers. Many such devices ... connectivity and modern technology. Older models force users to ...
(Date:11/21/2014)... Wash. , Nov. 20, 2014 C-Labs ... for the Internet of Things (IoT), today announced the ... of chief operating officer. Previously a strategic advisor to ... finance, and operations. Mr. Traynor is based out of ... . He reports to Chris Muench , Chief ...
(Date:11/18/2014)... The Parenteral Drug Association (PDA) today confirmed that seven officials ... least seven more will participate in the upcoming 2014 PDA ... Washington D.C. , Dec. 2-4. ... the regulatory agencies in the United States ... to help advance the use of metrics in the regulatory ...
Breaking Biology News(10 mins):Inception Technologies to Release New Biometric Reader 2C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2
... an estimated 665,000 deaths, mostly among African children. Now, ... for the world,s most useful antimalarial drug, artemisinin, giving ... cost of the live-saving drug in the future. , ... been slow due to high production costs of artemisinin. ...
... a hormone released by the lining of the stomach that ... obesity -- in fact, a vaccine that lowers ghrelin levels ... treatment for obesity. However, many people eat as a ... its effectiveness as a treatment for obesity may be reduced. ...
... pose considerable health threats to humans, and the heavy metal ... are exposed to it through plant-derived foods such as grains ... can reduce the amount of Cd found in the food ... in the Cell Press journal Trends in Plant Science ...
Cached Biology News:IU chemist develops new synthesis of most useful, yet expensive, antimalarial drug 2Low ghrelin -- reducing appetite at the cost of increased stress? 2Studies shed light on how to reduce the amount of toxins in plant-derived foods 2
RABBIT ANTI ISOCITRATE DEHYDROGENASE...
Recombinant Feline IL-5...
dithiothreitol (DTT) Reactive Dyes and Chemicals Thiol-Reactive Dyes, Haptens and Quenchers Reducing Agents...
Recombinant Feline IL-2, CF...
Biology Products: